Skip to main content
. 2021 Jul 26;9(7):e24651. doi: 10.2196/24651

Table 1.

General characteristics of the study data set.

Characteristic Candidemia events (n=501) Control (n=2000) P value
Sex, n (%)

.32

Male 297 (59.3) 1237 (61.9)

Female


Age (years), mean (SD) 59.5 (14.4) 55.9 (14.9) <.001
Hospital stay before culture (days), mean (SD) 23.0 (25.0) 22.2 (65.4) .66
Comorbidity, n (%)



Hepatic disease 60 (12.0) 298 (14.9) .11

Cardiovascular disease 68 (13.6) 203 (10.2) .03

Endocrine disease 54 (10.8) 198 (9.9) .62

Digestive disease 36 (7.2) 117 (5.8) .31

Respiratory disease 20 (4.0) 79 (4.0) >.999

Other disease 11 (2.2) 38 (1.9) .80
Charlson Comorbidity Index, mean (SD) 4.7 (2.3) 4.2 (2.2) <.001
Cancer origin site, n (%)



Lymphoid or hematopoietic 231 (46.1) 1116 (55.8) <.001

Digestive 153 (30.5) 551 (27.6) .20

Respiratory 43 (8.6) 113 (5.7) .02

Female genital 23 (4.6) 49 (2.5) .02

Other 38 (7.6) 122 (6.1) .27

Multiple primary 44 (8.8) 235 (11.8) .07
Metastatic lymph nodes, mean (SD) 5.1 (12.2) 3.5 (9.9) .007
Medication (days of therapy during 30 days before candidemia), mean (SD)

Steroid 8.6 (10.2) 5.8 (9.0) <.001

Immunosuppressant 1.4 (5.7) 1.6 (5.1) .43

Total peripheral nutrition 4.6 (7.8) 2.5 (5.8) <.001

Antibiotic use 16.9 (9.3) 15.3 (9.8) .002


Antianaerobic 10.1 (8.6) 5.5 (8.2) <.001


Broad spectrum cephalosporine: 3rd generation 3.5 (4.8) 2.6 (4.5) <.001


Carbapenem 4.8 (5.8) 2.5 (5.4) <.001


Extended spectrum penicillin 4.8 (5.8) 2.4 (5.1) <.001


Glycopeptide 3.8 (5.0) 1.8 (4.1) <.001
Vitals, mean (SD)



Systolic blood pressure (mmHg) 118.9 (23.4) 117.5 (20.8) .21

Diastolic blood pressure (mmHg) 68.5 (14.0) 68.6 (13.4) .89

Heart rate (bpm) 110.1 (21.3) 103.3 (20.6) <.001

Respiratory rate (brpm) 21.1 (5.1) 20.1 (4.2) <.001

Body temperature (°C) 37.2 (1.0) 37.6 (1.0) <.001

Peripheral capillary oxygen saturation (%) 96.2 (6.1) 97.0 (4.2) .03
Laboratory work-up, mean (SD)



Complete blood count




White blood cell count, blood (103/µL) 8.3 (11.2) 6.8 (18.0) .02


Hemoglobin, blood (g/dL) 9.4 (1.4) 9.7 (1.8) <.001


Platelet count, blood (10³/µl) 90.1 (103.1) 104.7 (151.0) .01


Segmented neutrophil (%) 62.3 (35.3) 54.0 (36.2) <.001


Absolute neutrophil count (10³/µL) 7.2 (10.3) 4.9 (7.5) <.001


Absolute lymphocyte count (10³/µL) 0.5 (0.7) 0.7 (1.6) .009

Acute phase reactants




Erythrocyte sedimentation rate (mm/h) 41.6 (36.8) 48.4 (34.3) .001


C-reactive protein (mg/dL) 11.2 (9.0) 8.6 (7.9) <.001


Procalcitonin, quantitative (ng/mL) 6.3 (16.3) 3.9 (14.4) .07

Coagulation




Prothrombin time (international normalized ratio) 1.4 (0.5) 1.3 (0.5) <.001

Chemistry




Total protein (g/dL) 5.3 (1.0) 5.8 (1.1) <.001


Albumin (g/dL) 2.9 (0.5) 3.4 (0.6) <.001


Globulin (g/dL) 2.3 (0.8) 2.5 (0.8) .001


Cholesterol (mg/dL) 129.1 (64.8) 138.4 (51.3) .006


Total bilirubin (mg/dL) 5.5 (9.1) 2.4 (4.7) <.001


Alkaline phosphatase (U/L) 183.1 (178.2) 157.9 (217.1) .007


Glucose fasting (mg/dL) 158.7 (71.2) 139.2 (59.2) <.001


Blood urea nitrogen (mg/dL) 34.1 (25.3) 22.8 (17.4) <.001


Creatinine (mg/dL) 1.1 (1.0) 1.0 (1.0) .01


Uric acid (mg/dL) 3.5 (2.3) 3.6 (2.4) .59


Calcium (mg/dL) 8.3 (0.8) 8.5 (0.8) <.001


Phosphorus (mg/dL) 3.1 (1.2) 3.2 (1.1) .03


Lactic acid (mmol/L) 2.9 (2.8) 2.2 (2.3) <.001
Other risk factors, n (%)



Candidemia history (within 30 days) 26 (5.2) 0 (0.0) <.001

Candida isolation from nonblood specimen (within 30 days) 110 (22.0) 132 (6.6) <.001

Central line inserted 223 (44.5) 854 (42.7) .50

Major operation (within 30 days) 78 (15.6) 219 (10.9) .005